Vertex Pharmaceuticals (NASDAQ:VRTX) Given New $525.00 Price Target at Truist Financial

Vertex Pharmaceuticals (NASDAQ:VRTX) had its price objective boosted by Truist Financial from $490.00 to $525.00 in a report published on Wednesday morning,Benzinga reports. The firm currently has a buy rating on the pharmaceutical company’s stock.

VRTX has been the subject of several other reports. Evercore raised their price objective on shares of Vertex Pharmaceuticals from $475.00 to $530.00 and gave the stock an “outperform” rating in a research report on Friday, January 23rd. Morgan Stanley boosted their target price on shares of Vertex Pharmaceuticals from $570.00 to $596.00 and gave the company an “overweight” rating in a report on Tuesday. Wells Fargo & Company increased their price target on shares of Vertex Pharmaceuticals from $460.00 to $515.00 and gave the company an “overweight” rating in a research note on Wednesday, December 10th. Sanford C. Bernstein reaffirmed an “outperform” rating and set a $577.00 price target on shares of Vertex Pharmaceuticals in a research report on Friday, February 13th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $590.00 price objective on shares of Vertex Pharmaceuticals in a report on Friday, February 13th. Twenty-three research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company. Based on data from MarketBeat.com, Vertex Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average price target of $553.36.

Vertex Pharmaceuticals Stock Performance

NASDAQ VRTX opened at $492.38 on Wednesday. The stock’s fifty day moving average is $469.19 and its two-hundred day moving average is $436.92. The firm has a market capitalization of $125.08 billion, a P/E ratio of 32.12 and a beta of 0.31. Vertex Pharmaceuticals has a fifty-two week low of $362.50 and a fifty-two week high of $519.68.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its earnings results on Thursday, February 12th. The pharmaceutical company reported $5.03 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $5.05 by ($0.02). Vertex Pharmaceuticals had a return on equity of 24.30% and a net margin of 32.94%.The company had revenue of $3.19 billion during the quarter, compared to analyst estimates of $3.18 billion. During the same period last year, the business earned $3.98 earnings per share. The firm’s revenue was up 9.5% compared to the same quarter last year. As a group, sell-side analysts forecast that Vertex Pharmaceuticals will post 15.63 EPS for the current year.

Insider Buying and Selling at Vertex Pharmaceuticals

In other news, EVP Duncan Mckechnie sold 4,910 shares of the business’s stock in a transaction that occurred on Wednesday, February 25th. The shares were sold at an average price of $487.65, for a total value of $2,394,361.50. Following the sale, the executive vice president directly owned 17,559 shares of the company’s stock, valued at approximately $8,562,646.35. The trade was a 21.85% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Jonathan Biller sold 945 shares of the stock in a transaction that occurred on Wednesday, February 25th. The stock was sold at an average price of $486.35, for a total transaction of $459,600.75. Following the transaction, the executive vice president directly owned 13,659 shares of the company’s stock, valued at $6,643,054.65. The trade was a 6.47% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 91,156 shares of company stock valued at $42,845,497. 0.20% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the company. Chesapeake Asset Management LLC raised its holdings in shares of Vertex Pharmaceuticals by 110.0% in the 3rd quarter. Chesapeake Asset Management LLC now owns 63 shares of the pharmaceutical company’s stock valued at $25,000 after buying an additional 33 shares during the period. Motiv8 Investments LLC purchased a new stake in Vertex Pharmaceuticals during the fourth quarter worth about $26,000. Colonial Trust Co SC lifted its position in shares of Vertex Pharmaceuticals by 118.8% during the third quarter. Colonial Trust Co SC now owns 70 shares of the pharmaceutical company’s stock worth $27,000 after purchasing an additional 38 shares in the last quarter. Swiss RE Ltd. acquired a new stake in shares of Vertex Pharmaceuticals during the fourth quarter worth about $28,000. Finally, Eagle Bay Advisors LLC purchased a new position in shares of Vertex Pharmaceuticals in the fourth quarter valued at approximately $29,000. 90.96% of the stock is currently owned by hedge funds and other institutional investors.

Key Vertex Pharmaceuticals News

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: Phase 3 RAINIER data for povetacicept showed a large (~52%) reduction in proteinuria in IgA nephropathy, boosting hopes for an expedited regulatory filing and expansion of Vertex into kidney disease — a clear fundamental catalyst. Vertex drug cuts proteinuria in Phase III IgA nephropathy trial
• Positive Sentiment: Multiple banks raised price targets and reiterated Buy/Outperform ratings after the trial (Morgan Stanley, BofA, Oppenheimer, Citigroup, HC Wainwright, Truist, Jefferies, etc.), increasing analyst upside and supporting further gains. Analyst price target coverage roundup
• Positive Sentiment: Broker commentary and coverage upgrades (e.g., new coverage from Jefferies, maintained/raised ratings at BMO and others) reinforce investor confidence in povetacicept’s commercial potential and Vertex’s pipeline diversification. BMO Capital sticks to Buy rating
• Neutral Sentiment: Company presentations at healthcare conferences (Barclays, Leerink transcripts published) provide management commentary and additional detail for investors, but contain no new trial data beyond the RAINIER release. Barclays conference transcript
• Neutral Sentiment: Coverage in market media noted Vertex’s rising biotech weight in Nasdaq indices and broader attention following the trial — visibility that can attract flows but also raise short‑term trading interest. Biotech focus rises in Nasdaq index
• Negative Sentiment: After the big rally, the stock is pulling back (broader coverage flagged a larger intraday fall vs. the market); this looks like classic profit‑taking/mean reversion after rapid gains, increasing short‑term volatility risk. Vertex registers a bigger fall than the market
• Negative Sentiment: Zacks and other outlets also noted that recent earnings estimate revision trends and any lingering execution questions could temper momentum, so some analysts caution that the upside may be paced by upcoming filings and commercialization visibility. Will this strength last?

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex’s marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.